Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-seven approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and forty-two supplementary protection certificates in seventeen countries.
Summary for Cipla
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 84 |
| Ingredients: | 84 |
| NDAs: | 97 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | CELECOXIB | celecoxib | CAPSULE;ORAL | 207446-001 | Sep 23, 2015 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cipla | ALENDRONATE SODIUM | alendronate sodium | TABLET;ORAL | 076768-001 | Aug 4, 2008 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cipla | PREGABALIN | pregabalin | CAPSULE;ORAL | 212280-002 | Jan 10, 2020 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Cipla | PHYTONADIONE | phytonadione | INJECTABLE;INJECTION | 212424-002 | Apr 22, 2022 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Cipla | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 210855-001 | Jul 16, 2018 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Cipla | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 211751-002 | Mar 23, 2020 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cipla | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 215592-002 | Sep 24, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008039473 | ⤷ Subscribe |
| Australia | 2008326297 | ⤷ Subscribe |
| Portugal | 2217610 | ⤷ Subscribe |
| Taiwan | 200927146 | ⤷ Subscribe |
| European Patent Office | 2217610 | ⤷ Subscribe |
| Israel | 205880 | ⤷ Subscribe |
| Denmark | 2217610 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0788511 | SPC/GB08/036 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| 2487163 | 122016000120 | Germany | ⤷ Subscribe | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1025 20150713 |
| 0582455 | 08C0021 | France | ⤷ Subscribe | PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213 |
| 2924034 | 2019018 | Norway | ⤷ Subscribe | PRODUCT NAME: DORAVIRIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV I KOMBINASJON MED LAMIVUDIN OG I KOMBINASJON MED TENOFOVIRDISOPROKSIL FUMARAT; REG. NO/DATE: EU/1/18/1333/001-2 20181213 |
| 0124495 | SPC/GB01/006 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1663240 | PA2015037,C1663240-2 | Lithuania | ⤷ Subscribe | PRODUCT NAME: RILPIVIRINO ARBA TERAPINIU POZIURIU PRIIMTINOS JO FORMOS, TOKIOS KAIP RILPIVIRINO DRUSKOS,ISKAITANT RILPIVIRINO HIDROCHLORIDA, TENOFOVIRO, YPAC TENOFOVIRO DIZOPROKSILIO FUMARATO, IR EMTRICITABINODERINYS; REGISTRATION NO/DATE: EU/1/11/737/001 2011-11-28, EU/1/11/737/002 20111128 |
| 2487166 | 2016/061 | Ireland | ⤷ Subscribe | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
